Navigation Links
Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
Date:2/6/2008

-- Study concludes there was no evidence of the development of viral resistance to R7128 after 2 weeks of monotherapy in hepatitis C patients --

PRINCETON, N.J., Feb. 6 /PRNewswire-FirstCall/ -- Pharmasset (Nasdaq: VRUS) and Roche will present the R7128 monotherapy resistance profile at the EASL-AASLD-APASL-ALEH-IASL Conference on Hepatitis B & C Virus Resistance to Antiviral Therapies being held in Paris, France from February 14-16, 2008. The scientific abstract for poster board no. 36, entitled "Lack of Viral Resistance after 14-day Monotherapy Treatment with R7128 in Treatment-experienced Patients Infected with HCV Genotype 1," is currently available on the conference website at http://www.easl.ch/hepatitis-conference/program/session1.asp. The poster presentation will be available for download in PDF format after it is presented on February 14, 2008 in the "Events & Presentations" section of Pharmasset's website at http://investor.pharmasset.com/events.cfm.

About R7128

R7128 is being developed for the treatment of chronic HCV infection through Pharmasset's collaboration with Roche. R7128 is a prodrug of PSI-6130, a nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified form of a molecule designed to enhance the absorption, distribution and metabolic properties of that molecule.

In a Phase 1 clinical trial, R7128 demonstrated potent, dose-dependent antiviral activity across four patient cohorts (n=40) receiving 750mg or 1500mg administered either once-daily or twice-daily for 2 weeks as monotherapy. The greatest mean decrease in HCV RNA from baseline was observed in the patient cohort that received 1500mg twice-daily, the highest dose of R7128 administered in the study. These patients experienced a mean 2.7 log10 IU/mL (>99%) decrease in HCV R
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Roche responds to announcement of IDEAL hepatitis C trial results
2. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
3. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
4. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
5. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
6. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
7. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
10. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
11. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...if.,Nov.25/PRNewswire/-- ChemoCentryx,Inc.,announ...sPROTECT-1(theProspectiveRandomizedOralTherapyEval...82-B)inpatientswithmoderate-to-severeCrohn,sdiseas...ndtolerabilityprofile.Thestudydemonstratedevidence...sdefinedasa70-pointdecreaseintheCrohn,sDiseaseActi...
(Date:11/24/2009)...4/PRNewswire/-- ,, WHAT:RomHoubens,aBelgianmant...ident,wasactuallyfullyconsciousandawakeduringthatt...eDynaVoxEyeMaxwasfeaturedinthesegmenttoillustrateh...unlockcommunication. ,, WHEN:GoodMorningAmerica...avoxtech.com ,, WHO:RomHoubenswasanengineer...
(Date:11/24/2009)....24/PRNewswire-FirstCall/--QuestDiagnosticsIncorpo...ostictesting,informationandservices,announcedthati...thcareConferenceinNewYorkCity.Thepresentationissch...Time. ,, Duringtheconference,thecompanywillreaf...,operatingincometoexceed18%ofrevenues,anddilutedea...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2Stereotactic Radiosurgery As Effective in Eliminating Parkinsons Disease Tremors As Other Treatments But Less Invasive 60570 1Stereotactic Radiosurgery As Effective in Eliminating Parkinsons Disease Tremors As Other Treatments But Less Invasive 60570 2Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and 26quot 3BArthritis Kits 26quot 3B 5937 1Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and 26quot 3BArthritis Kits 26quot 3B 5937 2Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and 26quot 3BArthritis Kits 26quot 3B 5937 3STAAR Surgical Generates 24464 000 in Cash from Operations During Third Quarter 5935 1STAAR Surgical Generates 24464 000 in Cash from Operations During Third Quarter 5935 2STAAR Surgical Generates 24464 000 in Cash from Operations During Third Quarter 5935 3STAAR Surgical Generates 24464 000 in Cash from Operations During Third Quarter 5935 4STAAR Surgical Generates 24464 000 in Cash from Operations During Third Quarter 5935 5STAAR Surgical Generates 24464 000 in Cash from Operations During Third Quarter 5935 6STAAR Surgical Generates 24464 000 in Cash from Operations During Third Quarter 5935 7STAAR Surgical Generates 24464 000 in Cash from Operations During Third Quarter 5935 8STAAR Surgical Generates 24464 000 in Cash from Operations During Third Quarter 5935 9STAAR Surgical Generates 24464 000 in Cash from Operations During Third Quarter 5935 10STAAR Surgical Generates 24464 000 in Cash from Operations During Third Quarter 5935 11STAAR Surgical Generates 24464 000 in Cash from Operations During Third Quarter 5935 12STAAR Surgical Generates 24464 000 in Cash from Operations During Third Quarter 5935 13STAAR Surgical Generates 24464 000 in Cash from Operations During Third Quarter 5935 14STAAR Surgical Generates 24464 000 in Cash from Operations During Third Quarter 5935 15STAAR Surgical Generates 24464 000 in Cash from Operations During Third Quarter 5935 16STAAR Surgical Generates 24464 000 in Cash from Operations During Third Quarter 5935 17STAAR Surgical Generates 24464 000 in Cash from Operations During Third Quarter 5935 18STAAR Surgical Generates 24464 000 in Cash from Operations During Third Quarter 5935 19STAAR Surgical Generates 24464 000 in Cash from Operations During Third Quarter 5935 20STAAR Surgical Generates 24464 000 in Cash from Operations During Third Quarter 5935 21STAAR Surgical Generates 24464 000 in Cash from Operations During Third Quarter 5935 22STAAR Surgical Generates 24464 000 in Cash from Operations During Third Quarter 5935 23STAAR Surgical Generates 24464 000 in Cash from Operations During Third Quarter 5935 24
...ented at ASCO Annual Meeting -, SOUTH SAN FRANCIS...ll/,-- Poniard Pharmaceuticals, Inc. (Nasdaq: PAR...gy, today announced safety and efficacy results,fr... of picoplatin and,liposomal doxorubicin in patien...ancer. Results demonstrated signals of clinical ac...
...cal Phase 2 data presented at American Society of ...eting, PRINCETON, N.J., June 1 Medarex, Inc.,(Na...llow-up and overall,survival (OS) results from a P...ilimumab in combination with dacarbazine (DTIC) wh...t or greater than 4 years of follow-up. This,inclu...
Other Medicine Technology:Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer 2Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer 3Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer 4Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer 5Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma 2Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma 3Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma 4
(Date:11/25/2009).../PRNewswire-USNewswire/--TheBlackAIDSInstituterece...veleadershipfor2010. ,, ThenewBoardMembersareah...olicy,law,finance,governmenthealthprograms,editori...omawiderangeofpersonalbackgroundsincludingbothhete...emselves,andrepresentingmultipleagegroups. ,, (...
(Date:11/25/2009)...dorsements,Business,andPressJoinEfforttoEducate ,...Onceagain,theNationalBipolarFoundationandtheMedicA...afe,tilStable"program,whichisnowbeingwidelyaccepte...Today,theNationalBipolarFoundationreceivedaproclam...mtheLt.GovernorofLouisianaMitchLandrieu.TheNationa...
(Date:11/25/2009)...evidence of a statistically significant survival b...e estrogen receptor (ER)-positive tumors had high ...18 (ER-alpha S118-P), according to a brief communi...l of the National Cancer Institute . , Approxima...oxifen. Preclinical studies have shown that ER-alp...
(Date:11/25/2009)...ood pressure? This simple question has been the f...ss-related gene Modulates High Blood Pressure in M...This simple question has been the focus of intense...r the first time established a link between a nove... to stress in mice as well as humans. The studies ...
(Date:11/25/2009)...o fight rheumatoid arthritis, could help newly dia...DAY, Nov. 25 (HealthDay News) -- A drug commonly u... arthritis now also shows some promise in helping ..., The drug, rituximab (Rituxan), helped patients k...gh the disease had destroyed some of their pancrea...
Breaking Medicine News(10 mins):Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:New stress-related gene modulates high blood pressure in mice and men 2Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3
...re Holdings,Inc. (Amex: PRZ ), one of the nation,...rgical solutions and services, today announced tha...PSHS Alpha Partners, Ltd., which,owns and operates...es have provided for the release of approximately ...
...ce Patient Safety, Improve Efficiency, SAN RAMON,...lobal services firm that specializes in enabling,t...tions, today announced,that it has been awarded a ... install clinical components of its Keane,InSight ...
...idan and Others Join Carlos Santana to ...BOCA RATON, Fla., Sept. 5 Spirit of Women Health,...unce today the opening of,bidding for the Spirit o...ing the National Stroke Association and,Peripheral...
...nvulsants, Especially When Prescribed,Off-Label, ... effective in treating bipolar disorder, fibromyal...scribed drugs are not always the best,initial choi...lic information project of Consumers Union., The ...
...tech,Incorporated (Nasdaq: MTEX ), a leading deve... care solutions, today announced a new sales tools...nt sales force of more,than 569,000 independent As... the company,s largest annual gatherings of,sales ...
...ders to Bicycle a Combined 3,000 Miles in Two Wee...Health and Hope, PHILADELPHIA, Sept. 5 It,s poss...rage, live less healthy and possibly,even shorter ...aths and affect the quality of life of more than 9...
Other Medicine News:Health News:PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers 2Health News:PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers 3Health News:PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers 4Health News:Keane Wins $1 Million Electronic Medical Record (EMR) Implementation at New Jersey-Based Acute Care Facility 2Health News:Keane Wins $1 Million Electronic Medical Record (EMR) Implementation at New Jersey-Based Acute Care Facility 3Health News:Online Celebrity Shoe Charity Auction for Women's Heart Health Opens Bidding 2Health News:Online Celebrity Shoe Charity Auction for Women's Heart Health Opens Bidding 3Health News:Consumer Reports' Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best 2Health News:Consumer Reports' Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best 3Health News:Mannatech Launches Phase One of New Sales and Training Tools 2Health News:Mannatech Launches Phase One of New Sales and Training Tools 3Health News:CIGNA Employees Take to the Road to Promote Health and Wellness 2Health News:CIGNA Employees Take to the Road to Promote Health and Wellness 3Health News:CIGNA Employees Take to the Road to Promote Health and Wellness 4
SAS Strep A Test
Poly stat Strep A
HemataSTAT
CoaguChek S
Medicine Products: